Literature DB >> 27333946

HDAC1, HDAC4, and HDAC9 Bind to PC3/Tis21/Btg2 and Are Required for Its Inhibition of Cell Cycle Progression and Cyclin D1 Expression.

Laura Micheli1, Giorgio D'Andrea1, Luca Leonardi1, Felice Tirone1.   

Abstract

PC3/Tis21 is a transcriptional cofactor that inhibits proliferation in several cell types, including neural progenitors. Here, we report that PC3/Tis21 associates with HDAC1, HDAC4, and HDAC9 in vivo, in fibroblast cells. Furthermore, when HDAC1, HDAC4, or HDAC9 are silenced in fibroblasts or in a line of cerebellar progenitor cells, the ability of PC3/Tis21 to inhibit proliferation is significantly reduced. Overexpression of HDAC1, HDAC4, or HDAC9 in fibroblasts and in cerebellar precursor cells synergizes with PC3/Tis21 in inhibiting the expression of cyclin D1, a cyclin selectively inhibited by PC3/Tis21. Conversely, the depletion of HDAC1 or HDAC4 (but not HDAC9) in fibroblasts and in cerebellar precursor cells significantly impairs the ability of PC3/Tis21 to inhibit cyclin D1 expression. An analysis of HDAC4 deletion mutants shows that both the amino-terminal moiety and the catalytic domain of HDAC4 associate to PC3/Tis21, but neither alone is sufficient to potentiate the inhibition of cyclin D1 by PC3/Tis21. As a whole, our findings indicate that PC3/Tis21 inhibits cell proliferation in a way dependent on the presence of HDACs, in fibroblasts as well as in neural cells. Considering that several reports have demonstrated that HDACs can act as transcriptional corepressors on the cyclin D1 promoter, our data suggest that the association of PC3/Tis21 to HDACs is functional to recruit them to target genes, such as cyclin D1, for repression of their expression. J. Cell. Physiol. 232: 1696-1707, 2017.
© 2016 Wiley Periodicals, Inc. © 2016 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 27333946     DOI: 10.1002/jcp.25467

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  9 in total

1.  Btg2 mutation induces renal injury and impairs blood pressure control in female rats.

Authors:  Matthew J Hoffman; Akiko Takizawa; Eric S Jensen; Rebecca Schilling; Michael Grzybowski; Aron M Geurts; Melinda R Dwinell
Journal:  Physiol Genomics       Date:  2022-05-03       Impact factor: 4.297

2.  The downregulation of putative anticancer target BORIS/CTCFL in an addicted myeloid cancer cell line modulates the expression of multiple protein coding and ncRNA genes.

Authors:  Evgeny Teplyakov; Qiongfang Wu; Jian Liu; Elena M Pugacheva; Dmitry Loukinov; Abdelhalim Boukaba; Victor Lobanenkov; Alexander Strunnikov
Journal:  Oncotarget       Date:  2017-09-02

3.  Interfering histone deacetylase 4 inhibits the proliferation of vascular smooth muscle cells via regulating MEG3/miR-125a-5p/IRF1.

Authors:  Xiangtao Zheng; Ziheng Wu; Ke Xu; Yihui Qiu; Xiang Su; Zhen Zhang; Mengtao Zhou
Journal:  Cell Adh Migr       Date:  2018-08-29       Impact factor: 3.405

4.  Genetic Interaction-Based Biomarkers Identification for Drug Resistance and Sensitivity in Cancer Cells.

Authors:  Yue Han; Chengyu Wang; Qi Dong; Tingting Chen; Fan Yang; Yaoyao Liu; Bo Chen; Zhangxiang Zhao; Lishuang Qi; Wenyuan Zhao; Haihai Liang; Zheng Guo; Yunyan Gu
Journal:  Mol Ther Nucleic Acids       Date:  2019-07-17       Impact factor: 8.886

5.  Piwi-interacting RNAs play a role in vitamin C-mediated effects on endothelial aging.

Authors:  Sulin Zheng; Haoxiao Zheng; Anqing Huang; Linlin Mai; Xiaohui Huang; Yunzhao Hu; Yuli Huang
Journal:  Int J Med Sci       Date:  2020-03-26       Impact factor: 3.738

Review 6.  Emerging role of anti-proliferative protein BTG1 and BTG2.

Authors:  Sang Hyeon Kim; In Ryeong Jung; Soo Seok Hwang
Journal:  BMB Rep       Date:  2022-08       Impact factor: 5.041

7.  Functional Genomics Identifies Tis21-Dependent Mechanisms and Putative Cancer Drug Targets Underlying Medulloblastoma Shh-Type Development.

Authors:  Giulia Gentile; Manuela Ceccarelli; Laura Micheli; Felice Tirone; Sebastiano Cavallaro
Journal:  Front Pharmacol       Date:  2016-11-30       Impact factor: 5.810

Review 8.  Tumor suppressors BTG1 and BTG2: Beyond growth control.

Authors:  Laurensia Yuniati; Blanca Scheijen; Laurens T van der Meer; Frank N van Leeuwen
Journal:  J Cell Physiol       Date:  2018-10-23       Impact factor: 6.384

9.  Clinical significance of HDAC1, -2 and -3 expression levels in esophageal squamous cell carcinoma.

Authors:  Huiwu Li; Hui Li; Yibulayin Waresijiang; Yan Chen; Ying Li; Liang Yu; Yike Li; Ling Liu
Journal:  Exp Ther Med       Date:  2020-04-29       Impact factor: 2.447

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.